POSTER LISTING - ISOP 2017 - Liverpoolisop2017liverpool.org/.../uploads/2017/09/ISOP2017_Poster-Listing.pdf · Nairobi, Kenya Catherine Wambura, Mbagathi Hospital, Kenya Theme: Pharmacogenomics

115 18 October 2017 | ACC, Liverpool, UK | www.isop2017liverpool.org

POSTER LISTING

Monday 16th October 2017

Poster No. Abstract / Paper Title / Presenter

Theme: Health data science including big data

1

Abstract 160Does a good institutional reporting culture extend to the reporting of yellow cardsTohfa Ahmad, West Midlands Centre For Adverse Drug Reaction Reporting, United Kingdom

2

Abstract 11Parents perception and practices regarding immunization: a cross sectional investigation Thamir Alshammari, University Of Hail, Saudi Arabia

3

Abstract 132Selective Serotonin Reuptake Inhibitors (SSRIs) and major congenital heart defects (CHDs): An analysis of FDA spontaneous adverse event report databases Sameh-Al-Zubedi, The University Of Jordan, Jordan

4

Abstract 148Does the use of vancomycin is efficient and safety in renal failure patients? Mehdi Bouhlel, National Center of Pharmacovigilance, Tunisia

5

Abstract 202The effect of concomitant antiepileptic drugs on plasma lamotrigine concentrationMehdi Bouhlel, National Center of Pharmacovigilance, Tunisia

6

Abstract 62Reducing prescribing errors associated with inpatient electronic prescribing systems: An investigation of pharmacist interventions to prevent prescribing errors Anthony Cox, University Of Birmingham, United Kingdom

192 posters have been successfully accepted for this years 17th ISoP Annual Meeting. Posters will be displayed in the exhibition hall

area with half of the posters being displayed on Monday and half of Tuesday. Official poster session times are:

Poster judging will take place during the conference and the three best posters will be awarded during the poster prize ceremony on

Wednesday, 18 October 13.00

Date Time

Monday 16th October 13:00 - 14:00

Tuesday 17th October 14:00 - 15:00

2 15 18 October 2017 | ACC, Liverpool, UK | www.isop2017liverpool.org

7

Abstract 119Proactive pharmacovigilance : description of nivolumabs safety informations identified through the clinical data warehouse of a French University Hospital Hlne Jantzem, Centre Rgional De Pharmacovigilance / Chru De Brest, France

8

Abstract 224Use of hospital data to estimate burden of adverse drug eventsMark Lillie, Cognizant, United Kingdom

9

Abstract 31Supporting pharmacovigilance by landscaping EU-funded real world dataKelly Plueschke, European Medicines Agency, United Kingdom

10

Abstract 27Multi-Level Modelling (MLM) in Specialist Cohort Event Monitoring (SCEM) studies Saad Shakir, Drug Safety Research Unit, United Kingdom

Theme: Miscellaneous

11

Abstract 87Safety of the hexavalent vaccine as used in general practice: Interim results from a prospective observational study Noemi Beatrix Bulik, Iuliu Hatieganu University Of Medicine And Pharmacy Cluj-Napoca, Romania

12

Abstract 83Bogota Declaration: The intention to promote both cooperation concerning safe use of medicines and pharmacovigilance development in Latin America Rosa Angela Caro-Rojas, Colombian Pharmacovigilance Association, Colombia

13

Abstract 241Drug-injury relief system for patient benefit in Taiwan: The 20 years of experience Wen Wen Chen, Taiwan Drug Relief Foundation, Taiwan

14

Abstract 30Deaths from medicines: A systematic analysis of UK Coroners reports to prevent future deaths Anthony Cox, University Of Birmingham, United Kingdom

15

Abstract 56Contraceptive and pregnancy testing requirements in clinical trials from French academic sponsors Sabrina Crepin, Chu De Limoges, France

16

Abstract 217Primary challenges to conducting post-marketing observational research in Sub-Saharan Africa: Preliminary results Laura Devore, DSRU, Switzerland

POSTER LISTING


POSTER LISTING

17

Abstract 267Disposal of unused and expired medicines by consumers Implications for ecopharmacovigilance Yvonne Yirenkyiwaa Esseku, Rapha Consult, Ghana

18

Abstract 9Olpadronate retrospective compilation of adverse events: Determination of Dose of Exposition (DOE) until the first adverse event occurrence Guadalupe Garca Darderes, Gador S.A., Argentina

19

Abstract 218Making safer medicines: Improving labeling and packaging to prevent medication errors Santiago Garnica, Vitalis, Colombia

20

Abstract 153Local success is global success Addressing the challenges of implementing product risk minimization globally Jeffrey Ho, Navitas, United Kingdom

21

Abstract 21Alternative facts: Why patient safety is under threat and what we can do about it Bruce Hugman, Uppsala Monitoring Centre, Thailand

22

Abstract 82Number Needed to Treat to Harm (NNTH) to assess the risk of cataracts associated with statins in observational studies Diogo Mendes, Aibili, Portugal

23

Abstract 116Overview of systematic reviews of therapeutic ranges: Establishing the threshold of increased drug toxicity James Moss, Bcuhb, United Kingdom

24

Abstract 112Assessment of cancer patients knowledge of the management of adverse reactions at the Mohammed V Rabat Military Instruction Hospital Naoual Nchinech, Mohamed V Military hospital, Morocco

25

Abstract 28Are NSAIDs really cheap medications? Marcelo Ponte, Pontificia Universidad Catolica Buenos Aires, Argentina

26

Abstract 12A way to classify the prescriptive cascades Marcelo Ponte, Pontificia Universidad Catolica Buenos Aires, Argentina


POSTER LISTING

27

Abstract 13Pevalence of prescriptive cascades Marcelo Ponte, Pontificia Universidad Catolica Buenos Aires, Argentina

28

Abstract 39Measuring the impact of product withdrawals and other major pharmacovigilance actions on public health burden in the EU: Methodological considerations Saad Shakir, Drug Safety Research Unit, United Kingdom

29

Abstract 44By selecting journals for monitoring by branches of medicine, MAHs can risk missing almost half of their ICSRs Katalin Timr-Horvth, Comfit Europe Ltd., Hungary

30

Abstract 45Big data of local medical literature monitoring Katalin Timr-Horvth, Comfit Europe Ltd., Hungary

31

Abstract 208Analysis and comparison of risk management tools Banu Unal, Bayer/Marmara University, Turkey

32

Abstract 109Latency period of crying following vaccination with MMR vaccine. What do spontaneous AEFI-reports show? Annet Van Boekel, Pharmacovigilance Center Lareb, Netherlands

33

Abstract 127Use of a medicine chart in promoting the safe use of Antiretrovirals amongst adults at Mbagathi Hospital in Nairobi, Kenya Catherine Wambura, Mbagathi Hospital, Kenya

Theme: Pharmacogenomics and pharmacovigilance

34

Abstract 97What do patients know about Yellow Cards?Alana Adams, YCC Wales, United Kingdom

35

Abstract 107Impact of serious adverse drug reactions on the quality of life of patients on HAART, in UMTH Maiduguri, North-East Nigeria Peter Bassi, University, Nigeria

36

Abstract 185Adverse events following Immunization: injection site abcesses Mehdi Bouhlel, National Center of Pharmacovigilance, Tunisia


POSTER LISTING

37

Abstract 264Clinical decision support tool for genetic HLA testing to predict, pre-empt and diagnose adverse drug reactions Gurpreet Ghattaoraya, University Of Liverpool, United Kingdom

38

Abstract 213A comparison of classification procedures and custom event terms in differentiating drug scheduling classes Eric Hung, Pfizer Inc, United States

40

Abstract 199Activity report of the pharmacovigilance unit of the Mohammed V Military Instruction Hospital Rabat Morocco May 2016 - March 2017Naoual Nchinech, Mohamed V Military hospital, Morocco

41

Abstract 66How do adverse drug reactions influence the patients daily life? Qualitative analysis on spontaneous reports by patients Len Rolfes, Netherlands Pharmacovigilance Centre Lareb, Netherlands

42

Abstract 159Non-medical prescriber experiences of training and competence to report adverse drug reactions Andrew Thompson, University Of Liverpool, United Kingdom

43

Abstract 252The role of pharmacovigilance in the development of pharmacogenetics treatments Banu Unal, Bayer/Marmara University, Turkey

Theme: Pharmacovigilance in specific settings (oncology, biologics, biosimilars, cell therapies, herbals

44

Abstract 104Oncogeriatric pharmacovigilance: a review of observational data Malak Abou Taam, Facult De Mdecine, Universit De Reims Champagne, France

45

Abstract 103Frail and elderly patient in oncology: Increased drug toxicities?Malak Abou Taam, Facult De Mdecine, Universit De Reims Champagne, France

46

Abstract 32Concurrent use of prescription medicines and herbal medicinal products among older adults: A systematic review Taofikat Agbabiaka, University Of Hertfordshire, United Kingdom

47

Abstract 203Adverse drug reactions reporting versus medication errors reporting in public hospitals using patient safety network system Fatima Albreiki, Abu Dhabi Health Services, United Arab Emirates


POSTER LISTING

48

Abstract 261Evaluation of the antimicrobial effect of expired oral antibioticsKawthar Alghasham, Pharmacist, Saudi Arabia

49

Abstract 244Ongoing elevated risk of developing tuberculosis in rheumatological conditions where Anti-TNF-alpha agents were used: Results of 2-year retrospective cohort studyVolkan Aydin, Marmara University School Of Medicine Department Of Pharmacology, Turkey

50

Abstract 242Reintroduction of reference infliximab product in patients showing inefficacy to its biosimilarSamy Babai, Pharmacovigilance, France

51

Abstract 37Dolutegravir withdrawal and adverse drug reactions: A retrospective study in Midi-PyrnesHaleh Bagheri, Service De Pharmacologie Mdicale Et Clinique, Centre De Pharmacovigilance, France

52

Abstract 35Towards web-based, purchase-event intensive monitoring for pharmacovigilance of Natural Health Products (NHPs): Lessons from development work Jo Barnes, University Of Auckland, New Zealand

53

Abstract 187Hypersensitivity reaction associated with intravenous administration of folinic acid in patient with gastric cancer Mehdi Bouhlel, National Center of Pharmacovigilance, Tunisia

54

Abstract 182Adverse drug reactions reports for trastuzumab: An analysis of Brazilian pharmacovigilance database and VigiBase/WHO and EudraVigilance/EMAFlvia Campos Barcelos, National Cancer Institute (INCA), Brazil

55

Abstract 198Unexpectedly high fatality rate in globally collected spontaneous reports of Progressive Multifocal Leukoencephalopathy with AlemtuzumabOla Caster, Uppsala Monitoring Centre, Sweden

56

Abstract 63The RE-AIM Framework and REVLIMID REMS program: A methodology for REMS assessmentMay Chan-Liston, Celgene Corporation, United States

57

Abstract 50Three cases of seizure with nivolumab: A new class of adverse effects for the anti-PD-1 immunotherapy?Vassili Chawadronow, Chu De Caen, France


POSTER LISTING

58

Abstract 142Data management in pharmacovigilance: Challenges and complexities Mugdha Chopra, Apcer Life Sciences, India

59

Abstract 7Application of the Bleeding Academic Research Consortium (BARC) Definition for bleeding outcomes within a post authorization safety studyMiranda Davies, Drug Safety Research Unit, United Kingdom

60

Abstract 90Natalizumab and rapidly evolving central nervous system lymphoma in VigiBaseBirgitta Grundmark, WHO-UMC, Sweden

61

Abstract 72Enhanced safety surveillance for seasonal influenza vaccines: A year-to-year comparison of suspected adverse drug reactions Lorna Hazell, DSRU Education & Research Ltd., United Kingdom

62

Abstract 250Alopecia during a spa: what link with INFLIXIMAB?Khadija Lechheb, Hopital Militaire Mohammed V, Morocco

63

Abstract 253Peripheral neuropathy and nails blue coloration under Folfiri-Bevacizumab khadija lechheb, Hopital Militaire Mohammed V, Morocco

64

Abstract 19Adverse drug reactions as a cause of admission to intensive care unit : A 4-months prospective cohort studyFrancoise Livio, Division Of Clinical Pharmacology, Switzerland

65

Abstract 58Suspected adverse reactions to herbal dietary supplements for weight loss collected by the Italian surveillance system on natural productsFrancesca Menniti-Ippolito, Italian National Institute Of Health, Italy

66

Abstract 57Suspected adverse reactions to alpha lipoic acid-containing food supplements: Analysis of the Italian Surveillance System of Natural Health ProductsFrancesca Menniti-Ippolito, Italian National Institute Of Health, Italy

67

Abstract 67Suspected adverse reactions to cannabis galenic preparations for medical use in Italy Francesca Menniti-Ippolito, Italian National Institute Of Health, Italy


POSTER LISTING

68

Abstract 145Guillain-Barr Syndrome associated with vaccines in children: A case-control studyFrancesca Menniti-Ippolito, Italian National Institute Of Health, Italy

69

Abstract 157Intussusception cases in an Italian pediatric populationFrancesca Menniti-Ippolito, Italian National Institute Of Health, Italy

70

Abstract 113Pharmacovigilance requirements for clinical trials in emerging markets in AsiaSanjeev Miglani, Apcer Life Sciences, India

71

Abstract 76Comparative safety of targeted therapies for mCRC treatment between young and elderly patients: A study using VigiBaseGhada Miremont Salame, Centre de Pharmacovigilance de Bordeaux, France

72

Abstract 85Safety of BRAF and MEK inhibitors for treatment of metastatic melanoma: Analysis of the WHO database of adverse eventsGhada Miremont Salame, Centre de Pharmacovigilance de Bordeaux, France

73

Abstract 101Utilisation and safety of Deferasirox (Exjade) in older adults: Results from an observational cohort study in England Saad Shakir, Drug Safety Research Unit, United Kingdom

74

Abstract 230Does the corossol fruit really treat cancer?Souad Skalli, Faculty of Science. Mohammed V University, Morocco

75

Abstract 233Launch of pilot reporting scheme for harms associated with new psychoactive substancesAlexander Smith, MHRA, United Kingdom

76

Abstract 144Epidemiological and clinical profile of adverse effects of antineoplastic agents, Pharmacovigilance in oncology, Morocco, 2012 2016Ismail Talibi, Ecole Nationale de Sant Publique de Rabat, Centre Anti Poison Et De Pharmacovigilance Du Maroc,

Morocco

77

Abstract 135Adverse drug reactions in oncology: Intensive monitoring program on biotechnological and target therapies in oncologic patients ALEXANDROS observational studyMarco Tuccori, University Hospital, Italy


POSTER LISTING

78

Abstract 130Infections and serious infections as risks of rituximab in rheumatoid arthritis. Results from an updated meta-analysis of randomised clinical trialsLuis Velez, University of Basel, Switzerland

79

Abstract 129Post-marketing safety of deferasirox in combo vs monotherapy, a comparative assessmentLuis Velez, University of Basel, Switzerland

80

Abstract 155Evaluation of compliance to the timing of childhood vaccinations following introduction of the Meningococcal B vaccine in the UK Jenny Wong, Medicines And Healthcare Products Regulatory Agency, United Kingdom

Theme: Social media, electronic media and pharmacovigilance

81

Abstract 117The Aspidium Project: A versatile app concept to support risk minimisation at patient levelJean-Christophe Delumeau, ISoP, Singapore

82

Abstract 24Awareness survey on pharmacovigilance: Design of an online program for Argentinean health care professionals Guadalupe Garca Darderes, Gador S.A., Argentina

83

Abstract 236Evaluation of the first EU-wide social media ADR awareness week: 7-11 November 2016 Mitul Jadeja, MHRA, United Kingdom

84

Abstract 196Baclofene safety and its use in social media: A preliminary study Agnes Lillo Le Louet, Fdration De Pharmacovigilance Ile De France, France

85

Abstract 262Estimating the pertinent information present in social media, not just what an algorithm detects Simon Maskell, University of Liverpool, United Kingdom

86

Abstract 263Looking longitudinally in Twitter: reading more than 140 characters Simon Maskell, University of Liverpool, United Kingdom

87

Abstract 196Safety profile of fractional dosing of yellow fever vaccine, experience from community based vaccine pharmacovigilance in Kinshasa Didier Nzolo Bomene, Unit Of Clinical Pharmacology and Pharmacovigilance, The Democratic Republic of Congo


POSTER LISTING

88

Abstract 126Risk management by using ADRs reports via social media Yaowares Oppamayun, Health Product Vigilance Center, Thailand

89

Abstract 133A clinician network for sharing patients experiences in pharmacovigilance: The PHARMACOWIKILANCE project Marco Tuccori, University Hospital, Italy

90

Abstract 189Abstract Impact of internet and social media use in pharmacovigilance Banu Unal, Bayer/Marmara University, Turkey

Theme: Training in pharmacovigilance

91

Abstract 128Off-label drug use and Adverse Drug Events (ADEs) in paediatric patients: An analysis of the Jordanian National Pharmacovigilance Database Sameh Al-Zubiedi, The University of Jordan, Jordan

92

Abstract 146Influencing adverse drug reaction reporting in primary care Christopher Anton, Yellow Card Centre West Midlands, United Kingdom

93

Abstract 34Turkish physicians pharmacovigilance and adverse drug reaction reporting knowledge, attitude, and practicesMberra Devrim Gner, Tobb Economy & Technology University Medical School, Turkey

94

Abstract 151Funding for neglected tropical diseases to boost pharmacovigilance staff capacity in low and middle income countriesJerry Liwono Yana, National Pharmacovigilance Centre, The Democratic Republic of Congo

95

Abstract 265Strengthening Collaborations for Operating Pharmacovigilance in Europe (SCOPE) joint action: Supporting medicines regulators in EU to improve public health Louise Loughlin, MHRA (SCOPE Joint Action), United Kingdom

96

Abstract 184Brazilian regulation in drug surveillance Ftima Roque, Institute of Biomedicine of University of Aveiro, Portugal


POSTER LISTING

Tuesday 17th October 2017

Poster No Abstract / Paper Title / Presenter

Theme: Clinical approaches in risk management

97

Abstract 143Effectiveness of clinical pharmacist review of direct oral anticoagulants prescriptions and scope of identified errors Ophir Lavon, Carmel Medical Center, Israel

98

Abstract 205Implementation of an integrative risk management plan for the safe practice of anticoagulants Ophir Lavon, Carmel Medical Center, Israel

99

Abstract 64Antibiotics use - Attitudes and practices of first year nursing students Ftima Roque, Institute of Biomedicine of University of Aveiro, Portugal

100

Abstract 73Adherence to therapeutic in outpatients: Literature review Ftima Roque, Institute of Biomedicine of University of Aveiro, Portugal

101

Abstract 186Safety and efficacy of different hyperkalaemia pharmacotherapies and their use in distinct clinical conditions Ftima Roque, Institute of Biomedicine of University of Aveiro, Portugal

102

Abstract 70Potentially inappropriate medicines in elderly patients - studies using the European screening tool, EU(7)-PIM list Ftima Roque, Institute of Biomedicine of University of Aveiro, Portugal

103

Abstract 222Contributing factors to the appearance of adverses events related to injectable Iron complexes Amina Tebaa, Centre Anti Poison Et De Pharmacovigilance, Morocco

Theme: Drug-induced organ specific injury (liver, skin, kidneys and other organs)

104

Abstract 106Cerebral pseudoatrophy, dementia and valproate Malak Abou Taam, Facult De Mdecine, Universit De Reims Champagne, France

105

Abstract 162idiosyncratic drug-induced liver injury: A 20-year update of the cases enrolled by the Spanish Dili registry Raul J. Andrade, Universidad De Malaga, Spain


POSTER LISTING

106

Abstract 163Analysing drug-host interplay in clinical presentation of drug-induced liver injury using data mining techniques Raul J. Andrade, Universidad De Malaga, Spain

107

Abstract 228Relevance of safety data in the withdrawal decision of hepatotoxic drugs Samy Babai, Pharmacovigilance, France

108

Abstract 234Generation of a novel, personalised in vitro model to assess the impact of mitochondrial DNA variation upon susceptibility to hepatotoxicity Amy Ball, University of Liverpool, United Kingdom

109

Abstract 174Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome induced by imatinib Mehdi Bouhlel, National Center of Pharmacovigilance, Tunisia

110

Abstract 214Fatal toxicity with a single IM dose of methotrexate in a patient treated for an ectopic pregnancy Mehdi Bouhlel, National Center of Pharmacovigilance, Tunisia

111

Abstract 231Fever, eosinophilia, and abnormal liver function are early signs suggestive of DRESS: A comparative study between DRESS and MPE Chia-Yu Chu, National Taiwan University Hospital, Taiwan

112

Abstract 237Mechanisms of chemotherapy-induced diarrhoea Stephanie French, University Of Liverpool, United Kingdom

113

Abstract 108Early onset vemurafenib-cobimetinib induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome: a case series Laurence Lagarce, Service de Pharmacologie Toxicologie et Pharmacovigilance CHU Angers Angers, France

114

Abstract 18Direct oral anticoagulants: Are they safer than vitamin K antagonists?Francoise Livio, Division Of Clinical Pharmacology, Switzerland

115

Abstract 223Abnormalities in liver or kidney function tests among patients treated for multi-drug resistant Tuberculosis in KinshasaYves Lula, Clinical Pharmacology And Pharmacovigilance Unit, The Democratic Republic of Congo


POSTER LISTING

116

Abstract 5Statins and diabetes: Are all statins at risk?Jean-Louis Montastruc, Facult De Mdecine De Toulouse, France

117

Abstract 247Profile of Allopurinol toxidermia: A series of 24 casesYoussef Moutaouakkil, Faculty Of Medicine And Pharmacy, University Mohammed V, Morocco

118

Abstract 249Toxic epidermal necrolysis due to betalactamins: 2 case reportsAmal Mrani Alaoui, Ibn Sina University Hospital, Morocco

119

Abstract 266Checkpoint Inhibitor induced thyroid immune related adverse events: Two distinct clinical patternsAnna Olsson-Brown, University Of Liverpool, United Kingdom

120

Abstract 110Hepatotoxicity associated with anti-tuberculosis drugs. A case series from hospitalized patients in Lima, PerTeodoro Oscanoa, Centro Investigacin Seguridad Medicamentos. FMH - IdI. Universidad San Martin De Porres,

Peru

121

Abstract 78Angiotensin II receptor blockers and psoriasis: An analysis of the French pharmacovigilance databaseThierry Trenque, Pharmacovigilance Department, France

122

Abstract 235Evaluation of the risk of Denosumab-associated HypocalcaemiaThierry Trenque, Pharmacovigilance Department, France

Theme: Miscellaneous

123

Abstract 105Safety and availability of codeine in FranceMalak Abou Taam, Ea 3797, Facult De Mdecine, Universit De Reims Champagne Ardenne, France

124

Abstract 138Comparative risk of cause-specific mortality in older patients prescribed codeine or tramadol for non-malignant pain: Retrospective cohort studyCraig Allen, Medicines And Healthcare Products Regulatory Agency (MHRA), United Kingdom

125

Abstract 115Disease-Modifying Antirheumatic Drugs (DMARDs) utilisation in autoimmune rheumatic diseasesLaura Alexandra Anghel, University Of Medicine And Pharmacy Iuliu Hatieganu- Faculty Of Pharmacy Ecoimma,

Romania


POSTER LISTING

126

Abstract 225Regulation of e-cigarettes: Ensuring patient safety and product qualityHelena Bird, Medicines And Healthcare Products Regulatory Agency, United Kingdom

127

Abstract 164Near real-time monitoring of the anticipated benefit-risk of vaccines using an interactive dashboard: A proposition from ADVANCEKaatje Bollaerts, P95, Belgium

128

Abstract 134Biological substantiation of antipsychotic-associated pneumonia: Literature review and computational analysesJanet Sultana, University Of Messina, Italy

Theme: Signal detection and evaluation

129

Abstract 141Bisphosphonate-induced carpal tunnel syndrome. A disproportionality analysis in VigiBaseAlfonso Carvajal, Universidad de Valladolid, Spain

130

Abstract 68Tailoring signal detection methodologies in a global database to focus on safety concerns reported by patientsRebecca Chandler, Uppsala Monitoring Centre - Who Collaborating Centre For International Drug Monitoring,

Sweden

131

Abstract 52Developing a signal detection and prioritisation triage logic for the Korea adverse event reporting system-foreign database: Results of pilot studyYunhui Do, Korea Institute Of Drug Safety & Risk Management, South Korea

132

Abstract 42HOPIPRAC, PRAC signals validation sentinel system, from a hospital data warehouseLayal El Aridi, Centre Rgional De Pharmacovigilance / Chru De Brest, France

133

Abstract 239A description of new safety signals detected and assessed by PRAC at EU level in 2014-2016Andreea Farcas, University Of Medicine And Pharmacy Cluj-Napoca, Romania

134

Abstract 95Do they all agree? Comparing expert signal assessmentBirgitta Grundmark, WHO-UMC, Sweden


POSTER LISTING

135

Abstract 61An example of robust pharmacovigilance practice: A safety signal of acute kidney injury with combination therapy of piperacillin/tazobactam and vancomycinSilke Harmeyer, Pfizer Inc, United Kingdom

136

Abstract 210Evaluation of a predictive model for suspected drug-drug interactions in routine signal detectionSara Hult, Uppsala Monitoring Centre, Sweden

137

Abstract 207Interaction between rosuvastatin and ticagrelor resulting in rhabdomyolysisSara Hult, Uppsala Monitoring Centre, Sweden

138

Abstract 125Spontaneous reporting characteristics of HIV Antiretrovirals in VigiBase: Disproportionate analysis between Sub-Saharan Africa and the Rest of the WorldAndrea Kuemmerle, Swiss Tropical And Public Health Institute, Switzerland

139

Abstract 4Challenges of identifying safety signals in clinical trials Milena Miljkovic, PrimeVigilance, Serbia

140

Abstract 6Impact of pharmacovigilance and evaluation activities - A regulatory perspectiveRania Mouchantaf, Health Canada, Canada

141

Abstract 161Safety of meningococcal group B vaccine: Experience from the UKSuzie Seabroke, Medicines & Healthcare Products Regulatory Agency, United Kingdom

142

Abstract 152Robustness of the CPA-PRR method in Pharmacovigilance detectionlodie Sole, French Medicines And Health Products Agency, France

143

Abstract 171Comparison of the performances of data-mining methods for signals detection on two spontaneous reporting databaseslodie Sole, French Medicines And Health Products Agency, France

144

Abstract 139An analysis of spontaneous reports on adverse drug reactions in child and adolescent psychiatry in GermanyThomas Stammschulte, Drug Commission Of The German Medical Association, Germany


POSTER LISTING

145

Abstract 147Muscular adverse drug reactions associated with proton pump inhibitors: A disproportionality analysis using the Italian National Network of Pharmacovigilance databaseMarco Tuccori, University Hospital, Italy

146

Abstract 29Characteristics of adverse events following influenza vaccination: Comparison between spontaneous reports and reports from an intensive monitoring programmeLeontine Van Balveren, Lareb, Netherlands

147

Abstract 22A change point analysis to study the reporting pattern of ADRs after drug substitutionFlorence Van Hunsel, Netherlands Pharmacovigilance Centre Lareb, Netherlands

148

Abstract 20An MCEM-MTL framework for drug safety signal filtering and detection in spontaneous reporting systemsCao Xiao, IBM T.J. Watson Research Center, United States

Theme: Spontaneous ADR reporting

149

Abstract 257The Chester experience - The impact of an intervention to improve adverse drug reactions reporting in a district general hospitalAmmar Abbas, Countess Of Chester Hospital NHS Foundation Trust, United Kingdom

150

Abstract 251Attitudes of non-medical nurse prescribers towards reporting adverse drug reactions via the yellow card scheme An exploratory studyAmmar Abbas, Countess Of Chester Hospital NHS Foundation Trust, United Kingdom

151

Abstract 38Adverse drug reactions related to direct oral anticoagulant: Patients internet narratives versus pharmacovigilance databaseHaleh Bagheri, Service De Pharmacologie Mdicale Et Clinique, Centre De Pharmacovigilance, France

152

Abstract 71Fetal impregnation with olanzapine: A case report Marie-Nolle Beyens, Pharmacovigilance, CHU de Saint-Etienne, France

153

Abstract 154Rabies vaccine-induced Adverse Drug Reactions (ADRs): What kind of serious ADRs?Marie-Nolle Beyens, Pharmacovigilance, CHU de Saint-Etienne, France

154

Abstract 197Evolution of the Western Cape Antiretroviral Pharmacovigilance Programme in South AfricaKaren Cohen, Division Of Clinical Pharmacology, Department Of Medicine, South Africa


POSTER LISTING

155

Abstract 140Spontaneous reporting of adverse drug reactions associated with newer long-acting injectable antipsychotics in ItalyPaola Maria Cutroneo, Regional Pharmacovigilance Centre, Italy

156

Abstract 167Safety profile of direct-acting antivirals for Hepatitis C: An analysis of Italian spontaneous reporting system databasePaola Maria Cutroneo, Regional Pharmacovigilance Centre, Italy

157

Abstract 40Adverse drug reactions of anticoagulants in Norway in a two year period (2013-2015)Anne Katrine Eek, Relis, Oslo University Hosptal, Norway

158

Abstract 53Applying DoTS adverse drug reactions classification to reports from hospital spontaneous stimulated reportingAndreea Farcas, University Of Medicine And Pharmacy Cluj-Napoca, Romania

159

Abstract 554 years medication error reporting by German pharmacists: A disproportionality analysisMatthias Ganso, Drug Commission Of German Pharmacists (AMK), Germany

160

Abstract 204ADRs and medication errors surveillance after the implementation of an electronic report system Lourdes Garza-Ocanas, Universidad Autonma De Nuevo Len, Mexico

161

Abstract 122Opinion of Costa Rican pharmacists regarding some aspects of the Spontaneous Adverse Drug Reactions reporting 2017Victoria Hall, University of Costa Rica, Costa Rica

162

Abstract 229Survey on physicians knowledge, attitude and practice towards Adverse Drug Reaction (ADR) reporting in the Middle EastAhmed Hegazy, Merck, United Arab Emirates

163

Abstract 121Patient ADR reporting through stakeholders lens: Experiences in different EU countriesPedro Inacio, University Of Helsinki, Finland

164

Abstract 158Recording and assessing medication errors within a spontaneous reporting system: First resultsUrsula Kberle, Drug Commission Of The German Medical Association, Germany


POSTER LISTING

165

Abstract 124Contribution of Adverse Events Reporting of HIV Antiretrovirals to VigiBase: Comparison between Sub-Saharan Africa and the rest of the WorldAndrea Kuemmerle, Swiss Tropical And Public Health Institute, Switzerland

166

Abstract 248Cardiac toxicity after long-term treatment with chloroquine in a lupus patient Khadija Lechheb, Hopital Militaire Mohammed V, Morocco

167

Abstract 201Pharmacovigilance and patients: How to improve reports quality? Agnes Lillo Le Louet, Fdration De Pharmacovigilance Ile De France, France

168

Abstract 114A description and comparison of the adverse drug reaction profiles in people living with HIV administered antitubercular and/or antiretroviral medicationsJosiah Tatenda Masuka, WHO, Belgium

169

Abstract 92An unexpected digoxin overdose probably caused by a drug-drug-interaction after amiodarone withdrawal and apixaban initiation: A case reportChristophe Maucorps, Pharmacovigilance CHU Caen Basse-Normandie France, France

170

Abstract 91A further case report of hepatotoxicity induced by carbimazole with a positive rechallengeChristophe Maucorps, Pharmacovigilance CHU Caen Basse-Normandie France, France

171

Abstract 93Two cases of optic neuritis under golimumab therapy (anti-TNFa) for ankylosing spondylitis reveling central demyelinating disordersChristophe Maucorps, Pharmacovigilance CHU Caen Basse-Normandie France, France

172

Abstract 77Serious drug adverse reactions: A retrospective and descriptive study from the French regions of Bordeaux, Limoges, and PoitiersGhada Miremont Salame, Centre de Pharmacovigilance de Bordeaux, France

173

Abstract 16Knowledge and attitude of health care professionals toward adverse drug reactions reporting at King Saud Medical CityKhaja Moinuddin, King Saud Medical City, Saudi Arabia

174

Abstract 8Drugs, adverse drug reactions and pharmacovigilance in the Adventures of TintinJean-Louis Montastruc, Facult De Mdecine De Toulouse, France


POSTER LISTING

175

Abstract 246Hemorrhagic stroke after thrombolysisAmal Mrani Alaoui, Ibn Sina University Hospital, Morocco

176

Abstract 221Hospital admission due to dysglycaemia among children in England and WalesAbdallah Naser, UCL School Of Pharmacy, United Kingdom

177

Abstract 111State of play on the reporting of adverse reactions of direct oral anticoagulants by doctors in Rabat (Morocco) in 2016Naoual Nchinech, Mohamed V Military hospital, Morocco

178

Abstract 168Challenges and resolutions in integrating electronic adverse drug reaction (ADR) reporting into UK clinical systems: A case studyRebecca Owen, MHRA, United Kingdom

179

Abstract 226Examination of the trends in medication error reporting post legislation changes in the United KingdomGowthamei Ragunathan, Medicines and Healthcare products Regulatory Agency, United Kingdom

180

Abstract 69Adverse drug reactions notifications by patientsFtima Roque, Institute of Biomedicine of University of Aveiro, Portugal

181

Abstract 65Rapid onset of very high INR values when roxithromycin prescribed with warfarin challenges the accepted mechanismMichael Tatley, New Zealand Pharmacovigilance Centre, University Of Otago, Dunedin, New Zealand

182

Abstract 219Methadone side effects and intoxication Amina Tebaa, Centre Anti Poison Et De Pharmacovigilance, Morocco

183

Abstract 51Eculizumab therapy and fatal seizures: About four cases Thierry Trenque, Pharmacovigilance Department, France

184

Abstract 23The contribution of direct patient reports to drug safety signals in the Netherlands from 2010-2015 Florence Van Hunsel, Netherlands Pharmacovigilance Centre Lareb, Netherlands


POSTER LISTING

185

Abstract 81The occurrence of ADRs of ADHD medication in the adult population: Collaboration with patient organisation contributing to medicine safety Gerda Weits, Netherlands Pharmacovigilance Centre Lareb, Netherlands

Theme: Womens health

186

Abstract 80Self-medication during the third trimester of pregnancy: A retrospective study Laurence Lagarce, Service de Pharmacologie Toxicologie et Pharmacovigilance CHU Angers, France

187

Abstract 118Breastfeeding women taking medications: About the need to collect data Gaboriau Louise, Regional Pharmacovigilance Center, France

188

Abstract 215Adverse events following immunization of pregnant women with Yellow Fever Vaccine in KinshasaDidier Nzolo Bomene, Unit Of Clinical Pharmacology and Pharmacovigilance, The Democratic Republic Of Congo

189

Abstract 256Medication errors in real clinical practice- Observational study among women undergoing assisted reproduction therapy Svetoslav Stoev, Medical University Sofia, Bulgaria

190

Abstract 96Intensive monitoring program of Teratogen and non-teratogen risk of drugs during pregnancy: The STORK projectMarco Tuccori, University Hospital, Italy

Theme: Health data science including big data

191

Abstract 43Patient Registries InitiativeKelly Plueschke, European Medicines Agency, United Kingdom

Theme: Pharmacogenomics and pharmacovigilance

192

Abstract 79Impact of weekly visits by Pharmacovigilance center pharmacist on questions about adverse drug reactions asked by intensive care unit practitionersLaurence Lagarce, Service de Pharmacologie Toxicologie et Pharmacovigilance CHU Angers, France

Documents

POSTER LISTING - ISOP 2017 - Liverpoolisop2017liverpool.org/.../uploads/2017/09/ISOP2017_Poster-Listing.pdf · Nairobi, Kenya Catherine Wambura, Mbagathi Hospital, Kenya Theme: Pharmacogenomics